Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Antonio Nino; Inaha Okuda; Timothy H Wilson; Lynn Yue; Hiromu Nakajima; Maho Tsuboi; Molly C Carr; Yutaka Seino

doi:10.1111/jdi.12749

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Journal of Diabetes Investigation ◽

10.1111/jdi.12749 ◽

2017 ◽

Vol 9 (3) ◽

pp. 558-566 ◽

Cited By ~ 1

Author(s):

Antonio Nino ◽

Inaha Okuda ◽

Timothy H Wilson ◽

Lynn Yue ◽

Hiromu Nakajima ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes Obesity and Metabolism ◽

10.1111/dom.13979 ◽

2020 ◽

Vol 22 (6) ◽

pp. 938-946 ◽

Cited By ~ 5

Author(s):

Juan Pablo Frias ◽

Michael A. Nauck ◽

Joanna Van ◽

Charles Benson ◽

Ross Bray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulinotropic Peptide

Download Full-text

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

Diabetes Obesity and Metabolism ◽

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

Diabetes Care ◽

10.2337/dc08-1961 ◽

2009 ◽

Vol 32 (7) ◽

pp. 1237-1243 ◽

Cited By ~ 84

Author(s):

M. A. Nauck ◽

R. E. Ratner ◽

C. Kapitza ◽

R. Berria ◽

M. Boldrin ◽

...

Keyword(s):

Type 2 Diabetes ◽

Body Weight ◽

Glycemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

Diabetes Obesity and Metabolism ◽

10.1111/dom.12235 ◽

2013 ◽

Vol 16 (5) ◽

pp. 418-425 ◽

Cited By ~ 32

Author(s):

T. Kadowaki ◽

K. Kondo

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2014.07.020 ◽

2014 ◽

Vol 106 (1) ◽

pp. 50-56 ◽

Cited By ~ 22

Author(s):

Takeshi Kadokura ◽

Noriko Akiyama ◽

Atsunori Kashiwagi ◽

Atsushi Utsuno ◽

Kenichi Kazuta ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Pharmacodynamic Study

Download Full-text

Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14480 ◽

2021 ◽

Author(s):

Annemie Stege Bojer ◽

Martin Heyn Sørensen ◽

Jenny Bjerre ◽

Peter Gæde ◽

Niels Vejlstrup ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diastolic Dysfunction ◽

Receptor Agonist ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13267 ◽

2018 ◽

Vol 20 (7) ◽

pp. 1770-1775 ◽

Cited By ~ 9

Author(s):

Shin‐ichi Harashima ◽

Nobuya Inagaki ◽

Kazuoki Kondo ◽

Nobuko Maruyama ◽

Makiko Otsuka ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Phase ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

Endocrine Journal ◽

10.1507/endocrj.ej14-0147 ◽

2014 ◽

Vol 61 (10) ◽

pp. 949-959 ◽

Cited By ~ 28

Author(s):

Yasuo Terauchi ◽

Yoichi Satoi ◽

Masakazu Takeuchi ◽

Takeshi Imaoka

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

Cardiovascular Diabetology ◽

10.1186/s12933-016-0425-2 ◽

2016 ◽

Vol 15 (1) ◽

Cited By ~ 31

Author(s):

Preman Kumarathurai ◽

Christian Anholm ◽

Olav W. Nielsen ◽

Ole P. Kristiansen ◽

Jens Mølvig ◽

...

Keyword(s):

Type 2 Diabetes ◽

Coronary Artery Disease ◽

Receptor Agonist ◽

Systolic Function ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Artery Disease

Download Full-text

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients

Diabetes ◽

10.2337/db18-2231-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2231-PUB

Author(s):

SASAN FAZELI ◽

NICOLE EHRHARDT

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text